Cargando…
Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial Drug
Plasmodium parasites undergo a clinically silent and obligatory developmental phase in the host’s liver cells before they are able to infect erythrocytes and cause malaria symptoms. To overcome the scarcity of compounds targeting the liver stage of malaria, we screened a library of 1037 existing dru...
Autores principales: | da Cruz, Filipa P., Martin, Cécilie, Buchholz, Kathrin, Lafuente-Monasterio, Maria J., Rodrigues, Tiago, Sönnichsen, Birte, Moreira, Rui, Gamo, Francisco-Javier, Marti, Matthias, Mota, Maria M., Hannus, Michael, Prudêncio, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308910/ https://www.ncbi.nlm.nih.gov/pubmed/22396598 http://dx.doi.org/10.1093/infdis/jis184 |
Ejemplares similares
-
Differential Effects of Antimalarial Drugs on Parasite Clearance Rates Are Reflected by Plasmodium falciparum Ring Ratio
por: Saidi, Alexuse M, et al.
Publicado: (2023) -
Robenidine Analogues Are Potent Antimalarials in Drug-Resistant
Plasmodium falciparum
por: Krollenbrock, Alina, et al.
Publicado: (2021) -
A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue
por: Sonoiki, Ebere, et al.
Publicado: (2017) -
Plasmodium falciparum Drug Resistance Phenotype as Assessed by Patient Antimalarial Drug Levels and Its Association With pfmdr1 Polymorphisms
por: Malmberg, Maja, et al.
Publicado: (2013) -
Plasmodium 18S Ribosomal RNA Biomarker Clearance After Food and Drug Administration–Approved Antimalarial Treatment in Controlled Human Malaria Infection Trials
por: Chavtur, Chris, et al.
Publicado: (2023)